Want to see NYMXF full AI Analyst Report?
Total Valuation
Nymox Pharmaceutical has a market cap or net worth of $18.91K. The enterprise value is $48.32.
Market Cap$18.91K
Enterprise Value$48.32
Share Statistics
Nymox Pharmaceutical has 94,540,140 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding94,540,140
Owned by Insiders―
Owned by Institutions―
Financial Efficiency
Nymox Pharmaceutical’s return on equity (ROE) is 0.66 and return on invested capital (ROIC) is 63.22%.
Return on Equity (ROE)0.66
Return on Assets (ROA)-6.87
Return on Invested Capital (ROIC)63.22%
Return on Capital Employed (ROCE)0.63
Revenue Per Employee0.00
Profits Per Employee-280.75K
Employee Count16
Asset Turnover0.00
Inventory Turnover0.00
Valuation Ratios
The current PE Ratio of Nymox Pharmaceutical is ―. Nymox Pharmaceutical’s PEG ratio is 0.04.
PE Ratio―
PS Ratio0.00
PB Ratio-1.38
Price to Fair Value-1.38
Price to FCF-3.60
Price to Operating Cash Flow>-0.01
PEG Ratio0.04
Income Statement
In the last 12 months, Nymox Pharmaceutical had revenue of 0.00 and earned -4.49M in profits. Earnings per share was -0.05.
Revenue0.00
Gross Profit-1.00K
Operating Income-4.28M
Pretax Income-4.49M
Net Income-4.49M
EBITDA-4.26M
Earnings Per Share (EPS)-0.05
Cash Flow
In the last 12 months, operating cash flow was -717.00K and capital expenditures 0.00, giving a free cash flow of -717.00K billion.
Operating Cash Flow-717.00K
Free Cash Flow-717.00K
Free Cash Flow per Share>-0.01
Dividends & Yields
Nymox Pharmaceutical pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta-351.33
52-Week Price Change-68.57%
50-Day Moving Average0.09
200-Day Moving Average0.07
Relative Strength Index (RSI)28.55
Average Volume (3m)21.72K
Important Dates
Nymox Pharmaceutical upcoming earnings date is May 15, 2024, TBA (Confirmed).
Last Earnings DateMar 29, 2024
Next Earnings DateMay 15, 2024
Ex-Dividend Date―
Financial Position
Nymox Pharmaceutical as a current ratio of 0.09, with Debt / Equity ratio of 0.00%
Current Ratio0.09
Quick Ratio0.09
Debt to Market Cap0.00
Net Debt to EBITDA0.02
Interest Coverage Ratio-18.95
Taxes
In the past 12 months, Nymox Pharmaceutical has paid 0.00 in taxes.
Income Tax0.00
Effective Tax Rate0.00
Enterprise Valuation
Nymox Pharmaceutical EV to EBITDA ratio is -2.18, with an EV/FCF ratio of -3.57.
EV to Sales0.00
EV to EBITDA-2.18
EV to Free Cash Flow-3.57
EV to Operating Cash Flow-3.57
Balance Sheet
Nymox Pharmaceutical has $74.00K in cash and marketable securities with $0.00 in debt, giving a net cash position of $74.00K billion.
Cash & Marketable Securities$74.00K
Total Debt$0.00
Net Cash$74.00K
Net Cash Per Share<$0.01
Tangible Book Value Per Share-$0.07
Margins
Gross margin is 0.00%, with operating margin of 0.00%, and net profit margin of 0.00%.
Gross Margin0.00%
Operating Margin0.00%
Pretax Margin0.00%
Net Profit Margin0.00%
EBITDA Margin0.00%
EBIT Margin0.00%
Analyst Forecast
The average price target for Nymox Pharmaceutical is ―, which is 11.43% higher than the current price. The consensus rating is ―
Price Target―
Price Target Upside―
Analyst Consensus―
Analyst Count0
Revenue Growth Forecast―
EPS Growth Forecast―